Experts shared their insights with Technology Networks, offering a glimpse into a future where automation and intelligence work hand in hand.
The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
Clinical Trials Arena on MSN
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback